Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company focused on gene-editing and cell therapy development, has announced it will release its first quarter 2025 financial results on Monday, May 12, 2025, after the US market closes. The financial results will be accessible through a press release in the Investors section of the company's website. Unlike typical earnings releases, Cellectis will not host a conference call to discuss the results, though their investor relations team will remain available to address questions via email at investors@cellectis.com.
Cellectis (NASDAQ: CLLS), un'azienda biotecnologica in fase clinica specializzata nello sviluppo di terapie cellulari e editing genetico, ha annunciato che pubblicherà i risultati finanziari del primo trimestre 2025 il lunedì 12 maggio 2025, dopo la chiusura del mercato statunitense. I risultati saranno disponibili tramite un comunicato stampa nella sezione Investitori del sito web aziendale. A differenza delle consuete comunicazioni sugli utili, Cellectis non terrà una conference call per discutere i risultati, ma il team di relazioni con gli investitori sarà comunque disponibile per rispondere alle domande via email all'indirizzo investors@cellectis.com.
Cellectis (NASDAQ: CLLS), una empresa biotecnológica en etapa clínica centrada en el desarrollo de terapias celulares y edición genética, ha anunciado que publicará sus resultados financieros del primer trimestre de 2025 el lunes 12 de mayo de 2025, después del cierre del mercado estadounidense. Los resultados estarán disponibles mediante un comunicado de prensa en la sección de Inversores del sitio web de la compañía. A diferencia de los comunicados habituales de resultados, Cellectis no realizará una llamada conferencia para discutir los resultados, aunque su equipo de relaciones con inversores estará disponible para responder preguntas por correo electrónico a investors@cellectis.com.
Cellectis(NASDAQ: CLLS)는 유전자 편집 및 세포 치료 개발에 중점을 둔 임상 단계의 바이오테크 회사로, 2025년 1분기 재무 실적을 2025년 5월 12일 월요일 미국 시장 마감 후에 발표할 예정이라고 밝혔습니다. 재무 실적은 회사 웹사이트 투자자 섹션의 보도자료를 통해 확인할 수 있습니다. 일반적인 실적 발표와 달리 Cellectis는 결과를 논의하기 위한 컨퍼런스 콜을 진행하지 않지만, 투자자 관계팀은 investors@cellectis.com 이메일을 통해 질문에 답변할 준비가 되어 있습니다.
Cellectis (NASDAQ : CLLS), une société biotechnologique en phase clinique spécialisée dans le développement de thérapies cellulaires et l'édition génétique, a annoncé qu'elle publiera ses résultats financiers du premier trimestre 2025 le lundi 12 mai 2025, après la clôture du marché américain. Les résultats financiers seront accessibles via un communiqué de presse dans la section Investisseurs du site web de l'entreprise. Contrairement aux communiqués de résultats habituels, Cellectis n'organisera pas de conférence téléphonique pour discuter des résultats, mais son équipe des relations investisseurs restera disponible pour répondre aux questions par e-mail à investors@cellectis.com.
Cellectis (NASDAQ: CLLS), ein biotechnologisches Unternehmen in der klinischen Phase mit Schwerpunkt auf Gen-Editing und Zelltherapieentwicklung, hat angekündigt, seine Finanzergebnisse für das erste Quartal 2025 am Montag, den 12. Mai 2025, nach Börsenschluss in den USA, zu veröffentlichen. Die Finanzergebnisse werden über eine Pressemitteilung im Investor-Bereich der Unternehmenswebsite zugänglich sein. Im Gegensatz zu üblichen Gewinnbekanntgaben wird Cellectis keine Telefonkonferenz zur Besprechung der Ergebnisse abhalten, jedoch steht das Investor-Relations-Team für Fragen per E-Mail unter investors@cellectis.com zur Verfügung.
Positive
None.
Negative
None.
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2025 ending March 31, 2025 on Monday, May 12, 2025 after the close of the US market.
Cellectis will not host a conference call to discuss these results. Our investors relations team remains available for questions at investors@cellectis.com
About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.
Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.
For further information on Cellectis, please contact:
Media contacts: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations contact: Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
